Introduction {#s1}
============

*Acinetobacter baumannii*, a Gram-negative coccobacillus usually found in soil and water, has emerged as a highly problematic nosocomial pathogen [@pone.0049534-Peleg1]. *A. baumannii* constitutes a major public health problem due to its intrinsic resilience to numerous drugs and its ability to readily acquire new resistance determinants [@pone.0049534-Dijkshoorn1], [@pone.0049534-Coyne1]. Multidrug-resistant *A. baumannii* resistant to carbapenem (MRAB-C) has been increasingly reported worldwide, which raises serious concern about the limited antimicrobial treatment options [@pone.0049534-Gordon1].

Multidrug efflux pumps belonging to the resistance-nodulation-cell division (RND) family have been shown to play an important role in the antimicrobial resistance of *A. baumannii* [@pone.0049534-Coyne1], [@pone.0049534-CortezCordova1]. To date, three different RND pumps have been identified in *A. baumannii*, namely AdeABC, AdeIJK and AdeFGH. AdeABC efflux pump is the first characterized RND system in *A. baumannii* [@pone.0049534-Coyne1]. Overexpression of the AdeABC efflux pump has been shown to pump out aminoglycosides, beta-lactam, fluoroquinolone, tetracycline, macrolide, chloramphenicol, trimethoprim, and even tigecycline (TGC). TGC is the first member of the glycylcycline and is considered a bacteriostatic drug with high efficacy in treating a broad range of antibiotic-resistant bacteria [@pone.0049534-Gordon1], [@pone.0049534-Yahav1]. Previous studies have shown that TGC has poor activities against MRAB-C due to over-expression of the AdeABC efflux pump system [@pone.0049534-Coyne1], [@pone.0049534-Wieczorek1], [@pone.0049534-Vila1], [@pone.0049534-Ruzin1], [@pone.0049534-Sun1], [@pone.0049534-Ruzin2]. The AdeIJK efflux pump contributes minimally to acquired resistance due to its toxicity for the host [@pone.0049534-DamierPiolle1]. The third efflux pump, AdeFGH, its overexpression confers high-level resistance to most antibiotics except β-lactam and aminoglycosides [@pone.0049534-Coyne2]. Its overexpression is therefore least expected to result in the multidrug resistance in MRAB-C isolates. The expression of AdeABC efflux pump is tightly regulated by the two-component system which contains a sensor kinase (SK) AdeS and a response regulator (RR) AdeR, encoded by the *adeRS* operon. The *adeRS* operon is located at the upstream of *adeABC* operon and is transcribed in the opposite direction [@pone.0049534-Coyne1], [@pone.0049534-Wieczorek1], [@pone.0049534-Marchand1]. The promoters of the *adeABC* operon and the *adeRS* operon were predicted at the region between the two operons [@pone.0049534-Marchand1].

In micro-organisms, the two-component system is a very important signal transduction system for adaptation to drastic and immediate changes in external or internal environmental conditions [@pone.0049534-Szurmant1]. This system is usually composed of a RR and a SK. The SK monitor\'s certain signal is caused by environmental changes. Signal bound to sensor domains of SK normally results in inducting an ATP dependent auto-phosphorylation of the histidine kinase domain in the catalytic core of the enzyme and transmitting the information to RR via a phosphoryl-transfer reaction to aspartate residue in RR. The RR is shifted to its active state by the phosphate group received and is directly bound to the promoter region of its target genes as a transcriptional regulator [@pone.0049534-Cheung1]. The typical type of SK is a homodimeric integral membrane protein in which the sensor domain, direct detection of extracellular signals, is formed by an extracellular loop contained between two membrane-spanning segments. The transmitter domain contains a histidine kinase A (HisKA) domain, and an ATP-binding domain follows the last transmembrane segment at the C-terminus and is localized within the cytoplasm [@pone.0049534-Szurmant1]. However, some SKs which deviate from the typical type of SK model with their sensor domains within the membrane or fully cytoplasmic are found in bacteria, fungi, and plant [@pone.0049534-Cheung1]. The cytoplasmic SK is a protein located in the cytoplasm comprising a sensor domain and transmitter domain, without a transmembrane domain [@pone.0049534-Cheung1], [@pone.0049534-Essen1], [@pone.0049534-Yang1], [@pone.0049534-Mern1], [@pone.0049534-Gorisch1].

Several families of Insertion sequence (IS) in *A. baumannii* have been associated with acquired antimicrobial resistance mechanisms [@pone.0049534-Adams1]. Many IS elements are related to antibiotic resistance through two mechanisms. Some of the IS elements contain promoters which can enhance the expression of their downstream antibiotic resistance genes [@pone.0049534-Poirel1]. IS*Aba1* has been found in upstream of *ampC*, *bla* ~OXA-23~, *bla* ~OXA-27~, *bla* ~OXA-51~ and *sul*II antibiotic resistance genes [@pone.0049534-Poirel1], [@pone.0049534-Hu1], [@pone.0049534-Corvec1], [@pone.0049534-Turton1], [@pone.0049534-Segal1], [@pone.0049534-Segal2], [@pone.0049534-Segal3], [@pone.0049534-Zhou1], [@pone.0049534-Lee1]. Other elements, such as IS*Aba2*, IS*Aba3*, and IS*Aba4* contain preceding promoters that enhance the expression of carbapenem resistant genes, *bla* ~OXA-58~ and the *bla* ~OXA-23~ genes [@pone.0049534-Chen1], [@pone.0049534-Poirel2], [@pone.0049534-Poirel3]. Moreover, the IS element may be inserted into and may disrupt the coding region of an outer membrane protein gene. The loss of the outer membrane protein results in resistance by blocking the input of antibiotics. Previous research described that an insertion mutation within the *carO* outer membrane protein gene by the IS*Aba1*, IS*Aba125*, or IS*Aba825* element was associated with carbapenem resistant [@pone.0049534-Poirel1], [@pone.0049534-Lee1], [@pone.0049534-Mussi1].

Previous studies found that IS*Aba1* insertion mutation within the *adeS* gene can enhance overexpression of the AdeABC efflux pump system and cause TGC resistant [@pone.0049534-Ruzin1]. Excessive transcription of *adeABC* operon was triggered due to a strong promoter in IS*Aba1* or the disruption of the AdeS protein. However, the detail mechanism regarding how the IS*Aba1* element controls the AdeABC efflux pump over- expression remains unknown. In the present study, we investigated the prevalence, genotype, AdeABC efflux pump expression and TGC resistance pattern of MRAB-C clinical isolates in which *adeRS* operon was uniquely destroyed by insertion of an IS element. Further, we identified a truncated cytoplasmic AdeS encoded by an extra operon driven by the promoter within the IS*Aba1* element. The truncated AdeS protein was then responsible for enhancing AdeABC efflux pump over- expression.

Materials and Methods {#s2}
=====================

Bacterial strains, growth media and plasmids {#s2a}
--------------------------------------------

A total of 317 distinct clinical isolates of MRAB-C were collected in this study at Tri-Service General Hospital from 2008 to 2010. The bacterial strains and plasmids used in this study are listed in [Table 1](#pone-0049534-t001){ref-type="table"}. Bacteria were grown routinely in Luria--Bertani (LB) broth (BD Difco, Franklin Lakes, NJ) at 37°C with shaking. Plasmids were maintained and selected in *E. coli* and *A. baumannii* hosts using a medium supplemented with the following antibiotics: ampicillin (Sigma-Aldrich, Poole, UK) (100 mg/L); kanamycin (Sigma-Aldrich) (50 mg/L); and tetracycline (Sigma-Aldrich) (5 mg/L).

10.1371/journal.pone.0049534.t001

###### Bacterial strains and plasmids used in this study.

![](pone.0049534.t001){#pone-0049534-t001-1}

  Strains or plasmids                                                                                                   Relevant characteristics                                                       Reference
  ----------------------------------- ----------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------
  *E. coli* strains                                  DH5α                      Φ80d, *lacZM15*, *endA1*, *recA1*,*hsdR17* (r−, m+), supE44, thi-1, gyrA96, relA1, F-- (lacZYA- argF)U169               Lab stock
  *Acinetobacter baumannii* strains               ATCC 15151                                                        *A. baumannii* reference strain                                                      ATCC
                                                    ABmut02                                 Derived from BCRC15884. *adeRS* mutant obtained by plasmid insertion. KanR, AmpR                          This study
                                                     AB039                                    clinical MDR strain, TGC MIC = 2 mg/L, *adeRS* without IS element insertion                      
                                                     AB090                                clinical MDR strain, TGC MIC = 1 mg/L, *adeS* mutant obtained by IS*aba*1 insertion                         This study
                                                     AB096                                    clinical MDR strain, TGC MIC = 16 mg/L, *adeRS* without IS element insertion                     
                                                     AB260                                clinical MDR strain, TGC MIC = 1 mg/L, *adeS* mutant obtained by IS*aba*1 insertion                         This study
                                                     AB293                                clinical MDR strain, TGC MIC = 16 mg/L, *adeS* mutant obtained by IS*aba*1 insertion                        This study
                                                     AB392                               clinical MDR strain, TGC MIC≦ 0.5 mg/L, *adeR* mutant obtained by IS*aba125* insertion                       This study
  Plasmids                                          pMU125                                    *E. coli-Acinetobacter* shuttle plasmid with A. baumannii replication origin                      [@pone.0049534-Dorsey1]
                                                  pCR2.1-Topo                                                Suicide plasmid for *A. baumannii*. KanR, AmpR                                           Invitrogen
                                               pCR2.1-*adeR*int                                pCR2.1-Topo containing a 513-bp internal fragment of the adeR. KanR, AmpR                              This study
                                                    pYM102                                                          mini-CTX::*lacI^q^*-P~T7~-*lacZ*                                            [@pone.0049534-Morita1]
                                                     pS01                       *E. coli-Acinetobacter* shuttle plasmid with *A. baumannii* replication origin; mini-CTX::lacIq-PT7-lacZ              This study
                                               pRS-*adeRS* (wt)                               Derived from pRS, mini-CTX:: *adeRS*-P*ade*-*lacZ* (*adeRS* from ATCC 15151)                            This study
                                              pRS-*adeRS* (AB090)                                Derived from pRS, mini-CTX:: *adeRS*-P*ade*-*lacZ* (adeRS from AB260)                                This study
                                              pRS-*adeRS* (AB293)                               Derived from pRS, mini-CTX:: *adeRS*-P*ade*-*lacZ* (*adeRS* from AB293)                               This study
                                                pRS-*adeR* (wt)                                Derived from pRS, mini-CTX:: *adeR*-P*ade*-*lacZ* (*adeR* from ATCC 15151)                             This study
                                              pRS-*adeR* (AB260)                                 Derived from pRS, mini-CTX:: *adeR*-P*ade*-*lacZ* (*adeR* from AB260)                                This study
                                              pRS-*adeR* (AB293)                                 Derived from pRS, mini-CTX:: *adeR*-P*ade*-*lacZ* (*adeR* from AB293)                                This study
                                       pRS-P*ade*-Pout-truncated *adeS*    Derived from pRS-adeRS (AB293), *Sph*I digested and self-ligatioin. mini-CTX:: truncated *adeS*-P*out*-Pade-*lacZ*         This study
                                          pRS-P*out*-truncated *adeS*                     Derived from pRS, mini-CTX:: truncated *adeS* -Pout-*lacZ* (soluble adeS from AB293)                        This study
                                       pRS-P*out*-truncated *adeS* (SDM)      Derived from pRS_P*out*\_truncated *adeS*, mutated at the start code ATG to AAG by site-directed mutagenesis            This study

Antimicrobial susceptibility tests {#s2b}
----------------------------------

All bacterial cultures were prepared on the day of antimicrobial susceptibility testing. The U.S. Food and Drug Administration (FDA) recommended tigecycline (TGC) susceptibility breakpoints for *Enterobacteriaceae* (susceptible MIC, ≦2 g/L; intermediate MIC, \>2 and \<8 g/L; resistant MIC, ≧8 g/L) were used as MIC interpretation criteria. TGC (Wyeth, Madison, NJ) powder was obtained from commercial sources and was prepared in a solution with sterilized water, and the solution was then frozen in aliquots at −80°C. TGC MICs were initially determined by the E-test (AB Biodisk, Solna, Sweden) and confirmed by the agar dilution test using Mueller-Hinton II agar (BD Difco). Susceptibility tests of other antimicrobials were performed by the VITEK-2 system (bioMérieux, Marcy l\'Etoile, France). All strains were tested for susceptibility to the following antibiotics: ampicillin, cefazolin, gentamicin, amikacin, ampicillin/sulbactam, piperacillin/tazobactam, trimethoprim/sulfamethoxazole, ceftazidime, ceftriaxone, imipenem, ciprofloxacin, cefepime, nitrofurantoin, tigecycline and levofloxacin. To verify the over- expression of efflux pump, we prepared Mueller--Hinton (M-H) agar plates with and without adding the efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine (NMP) (Sigma-Aldrich). The final concentration of NMP in the M-H agar was 64 mg/L. The MICs of TGC in the presence or absence of NMP were determined by the E-test described above.

DNA manipulations {#s2c}
-----------------

Genomic DNA was isolated using the protocol suggested in the literature [@pone.0049534-Syn1]. Plasmid DNA was isolated by the Viogene plasmid DNA extraction miniprep system (Viogene biotek corporation, Taiwan). DNA concentration measurements were performed with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA). Standard PCR amplifications were performed with the DyNAzyme DNA polymerase (Finnzymes, Espoo, Finland). When necessary, high fidelity and blunt-ended PCR products were amplified with Phusion DNA Polymerase (Finnzymes). PCR products were purified with Virogene Gel and PCR Clean-Up kit (Viogene). Oligonucleotide was synthesized by Genomics BioScience and Technologies, Inc. (Taiwan). All oligonucleotides used in the study are listed in [Table 2](#pone-0049534-t002){ref-type="table"}. Thermal cycle reactions were performed using the 9700 GeneAmp thermocycler (Applied Biosystems, Foster City, CA). Nucleotide sequencing was performed with BigDye Terminator Cycle Sequencing kit (Applied Biosystems) according to the manufacturer\'s instructions. Capillary electrophoresis was performed with a 3730XL Genetic Analyzer (Applied Biosystems) and then analyzed by BioEdit software (<http://www.mbio.ncsu.edu/BioEdit/bioedit.html>). Restriction enzymes were purchased from New England Biolabs (New England Biolabs, Beverly, MA) and used according to the manufacturer\'s recommendation. Fast-Link DNA Ligation Kit was purchased from Epicentre (Epicentre, Madison, Wisconsin) and used according to the manufacturer\'s recommendation. Competent cells were prepared and transformed by electroporation as previously described [@pone.0049534-Aranda1]. The sequence was analyzed with the NCBI BlastX bioinformatic tool (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) and the NCBI open reading frame (ORF) finder (<http://www.ncbi.nlm.nih.gov/projects/gorf/>).

10.1371/journal.pone.0049534.t002

###### Oligonucleotides used in this study.

![](pone.0049534.t002){#pone-0049534-t002-2}

  Primer name                                Sequence                                                                                        Features/purpose                                                                                   Source
  --------------------------- -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------
  adeRS_1f                          ATGTTTGATCATTCTTTTTCTTTTG                                          Detection the IS element insertion within the *adeRS* operon and Sequencing of *adeRS* operon                                    [@pone.0049534-Peleg2]
  adeRS_1849r                       TTAGTTATTCATAGAAATTTTTATG                                                                                                                                                                          
  adeRS_689r                          TTAATTAACATTTGAAATATG                                                                                                                                                                            
  adeRS_776f                       ATGAAAAGTAAGTTAGGAATTAGTAAG                                                                                                                                                                         
  ISAba1-F                           CATTGGCATTAAACTGAGGAGAAA                                             with ade RS_1849r primer to confirme the nsertion of IS*aba1* within the *adeS* operon                                              This study
  ISAba1-R                             TTGGAAATGGGGAAAACGAA                                                with ade RS_1f primer to confirme the insertion of IS*aba1* within the *adeS* operon                                               This study
  pWH1266_ori_PstI_F               GCCTGCAGGATCGTAGAAATATCTATGA                                            Cloning of *A. baumannii* replication origin from pMU125 with engineered *Pst*I site                                               This study
  pWH1266_ori_PstI_SmaI_R      AACTGCAGACCCGGGGGATTTTAACATTTTGCGTTG                                                                                                                                                                    
  AdeA_promoter_f\_BamHI        CACGGATCCAACCTAGTGAGTTTTTGATGTTCG                               Cloning *adeRS* operon and promoter *ade* with engineered SmaI and BamHI site into pRS to form pRS- *adeRS*                                   This study
  AdeS_r\_SmaI                  CGCCCCGGGTTAGTTATTCATAGAAATTTTTATG                                                                                                                                                                     
  AdeR_r\_SmaI                  CACCCCGGGTATTTAGGCGTCATCTTTTACAGC            With AdeA_promoter_f *Bam*HI primer to clone *adeR* operon and promoter ade with engineered *Sma*I and *Bam*HI site into pRS to form pRS- *adeR*                 This study
  ISaba1Pout_f\_BamHI              CACGGATCCAAGCATGATGAGCGCAAAG       With AdeS_r *Sma*I primer to clone soluble *adeS* operon and IS*aba1* P*out* with engineered *Sma*I and *Bam*HI site into pRS to form pRS-P*out*-soluble *adeS*         This study
  adeR_6f                         TGATCATTCTTTTTCTTTTGATTGCCAAGA                                               Cloning the partial sequence of *adeR* into pCR2.1- Topo to form pTOPO*adeR*                                                   This study
  adeR_514r                           CAGTCAGCGTCAGATTAAGCA                                                                                                                                                                            
  adeA_F                             TTGATCGTGCTTCTATTCCTCAAG                                                                             RT- PCR of *adeA* gene                                                                       
  adeA_R                              GGCTCGCCACTGATATTACGTT                                                                                                                                                                           
  adeB_F                               GGATTATGGCGACAGAAGGA                                                                               RT- PCR of *adeB* gene                                                                       
  adeB_R                               AATACTGCCGCCAATACCAG                                                                                                                                                                            
  QPCR_adeRS1661_f                      ACCGAGTTCCAAGACGAT                                                                                RT- PCR of *adeS* gene                                                                              This study
  QPCR_adeRS1782_r                      CCTTTCAGTGCCACAATA                                                                                                                                                                             
  QPCR_adeR96_f                        AAAACGTGAAGGCATGAGTG                                                                               RT- PCR of *adeR* gene                                                                              This study
  QPCR_adeR220_r                       CTTCCCAACCGTTTAATTCG                                                                                                                                                                            
  rpoB_f                               TCCGCACGTAAAGTAGGAAC                                                                               RT- PCR of *rpoB* gene                                                                       
  rpoB_r                               ATGCCGCCTGAAAAAGTAAC                                                                                                                                                                            
  TruncatedAdeS_SDMut_sense      ATAATTTTAATGATAAGGCTCAAA**A**GC                                change the start code ATG to AAG in soluble *adeS* by site-directed mutagenesis at pRS-Pout-soluble *adeS*                                    This study

Quantitative real-time PCR {#s2d}
--------------------------

To detect the expression of *adeR, adeS, adeA and adeB* gene, quantitative real-time RT-PCR was performed individually for each. Primers for the quantitative real-time were designed using Primer3 software. The efficiency of each primer pair in quantitative real-time PCR has been determined by a 10-fold serial dilution of the template. By plotting the log values of template concentrations on the x-axis and the Ct values on the y-axis, standard linear lines with slopes (m) ranging from −3.58 to −3.27 were obtained. We obtained 95.1∼105.0% amplification efficiencies (E~Amp~) for the primer pairs based on the calculation equation, E~Amp~ = 10^−1/m^−1. *A. baumannii* cells were grown aerobically in LB broth until reaching the mid-log phase. DNaseI-treated RNA templates were prepared using an RNeasy kit (QIAGEN Sciences, MD). The concentrations of the RNA were quantified with a spectrophotometer. Reverse transcription was performed using a high-capacity cDNA archive kit (Applied Biosystems) with 200 ng of RNA in a 20 µL reaction mixture containing 1× (each) reverse transcription buffer, deoxynucleoside triphosphate mix, and random primers as well as 2.5 U/ml multiscribe reverse transcriptase. Negative-control reactions included equal concentrations of RNA and all reagents while omitting reverse transcriptase. Incubation for 10 min at 25°C followed by 2 h at 37°C was carried out with a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems). Real time PCR was performed with the DyNAmo™ Flash SYBR Green qPCR Kit (Finnzymes) and a 1∶10 final dilution of the cDNA product on the ABI PRISM 7500 Real-Time PCR system (Applied Biosystems). Each PCR analysis contained one primer pair. Cycling conditions were as follows: denature at 95°C for 10 min, followed with 40 cycles of denature at 95°C for 15 s and annealing/extension at 56°C for 30 s, and finalized with 1 cycle at 95°C for 30 s and 28°C for 30 s. Following PCR cycling, melting point data were collected and the dissociation curve was examined for each well. The critical threshold cycle (Ct) numbers were determined by Sequence Detection Systems version 2.2.2 (Applied Biosystems). In order to omit efficiency variation among primer pairs, ΔCt and ΔΔCt were applied for comparing the gene expression level. The ΔCt for gene expression was calculated against that for the *rpoB* housekeeping gene, and the ΔΔCt was calculated against that for the TGC-susceptible control strain (ATCC 15151, wt) as suggested in the literature.

Knockout the *adeRS* operon by homologous recombination {#s2e}
-------------------------------------------------------

Plasmid inserted with the *adeRS* operon of *A. baumannii* was carried out as previously described [@pone.0049534-Aranda1]. Briefly, kanamycin and ampicillin resistant plasmid pCR2.1-Topo, unable to replicate in *A. baumannii*, was used as a suicide vector. An internal fragment (513 bp) of the *adeR* gene was amplified by PCR with AdeR_6f and AdeR_514r primers ([Table 2](#pone-0049534-t002){ref-type="table"}) from a template of *A. baumannii* ATCC 15151 genomic DNA. The PCR product was cloned into the pCR2.1-Topo vector and electroporated into *E. coli* to yield the pCR2.1-*adeR*int plasmid ([Table 1](#pone-0049534-t001){ref-type="table"}). Recombinant plasmid (100 ng) was then introduced in the kanamycin and ampicillin susceptible *A. baumannii* ATCC 15151 by electroporation [@pone.0049534-Aranda1]. Mutants were selected on LB agar plates containing kanamycin and ampicillin. Inactivation of the *adeRS* operon by insertion of the plasmid via a single crossover recombination was confirmed by sequencing the amplified PCR products with the AdeA_promoter_f\_*BamH*I and AdeRS_1849r primer pairs ([Table 2](#pone-0049534-t002){ref-type="table"}).

Construction of the *E. coli*-*Acinetobacter* shuttle vector pS01 {#s2f}
-----------------------------------------------------------------

The DNA fragment of *A. baumannii* replication origin was obtained by PCR using primers pWH1266_ori\_*Pst*I_F and pWH1266_ori\_*Pst*I\_*Sma*I_R ([Table 2](#pone-0049534-t002){ref-type="table"}) in a reaction mixture (50 µL) containing 1 U of Phusion DNA Polymerase, 0.2 mM of each deoxynucleoside triphosphate, 1× PCR buffer, 5 pmol of each primer, 2 mM MgSO~4~ and 10 ng of pMU125 DNA as the template [@pone.0049534-Dorsey1]. For PCR, the reaction mixture was subjected to an initial 1 min denaturation step at 98°C, followed by 35 cycles of 10 s at 98°C, 10 s at 55°C, and 30 s at 72°C and a 10 min final elongation at 72°C. The purified PCR product was then cloned into plasmid pYM102 through the *Pst* I site. The resulting construct, pS01, was sequenced to verify the absence of PCR-introduced mutations.

Construction of pRS series for expressing the *adeRS*, *adeR* and Pout-truncated *adeS* genes {#s2g}
---------------------------------------------------------------------------------------------

The plasmid pS01 was digested with *Sma*I and *Bam*HI for 2 h at 37°C (or 25°C in the case of *Sma*I) to delete its *lacI* ^q^ gene and T7 early gene promoter. The digested plasmids were ligated with the respective gene fragments to generate a series of recombinant pRS clones, including pRS-*adeRS* (wt), pRS-*adeRS* (AB090), pRS-*adeRS* (AB293), pRS-*adeR* (wt), pRS-*adeR* (AB260), pRS-*adeR* (AB293) and pRS-*P*out-truncated\_*adeS*. The *adeRS* and *adeR* gene fragments of ATCC 15151 and AB260 were amplified by PCR using common forward primer AdeA_promoter_f\_*Bam*HI with reverse primers AdeS_r\_*Sma*I and AdeR_r\_*Sma*I, respectively ([Table 2](#pone-0049534-t002){ref-type="table"}). The Pout-truncated *adeS* gene fragment of AB293 was amplified by PCR using primers IS*Aba1*Pout_f\_*BamH*I and AdeS_r\_*Sma*I. Another plasmid pRS-Pade-Pout-truncated *adeS* was obtained by splicing out the DNA fragment between *P*ade and *P*out of ISAbaI in pRS-*adeRS* (AB293) with *Sph*I digestion and re-ligation.

Site Directed Mutagenesis {#s2h}
-------------------------

The site-directed mutagenesis (SDM) protocol was modified from the previous study [@pone.0049534-Zheng1]. We used plasmid pRS-Pout-truncated *adeS* as the template for SDM to disrupt start codon (ATG to AAG). The plasmid was amplified using a mutation bearing primer TruncatedAdeS_SDMut_sense in PCR reaction mixture (25 µL) containing 1 µg template, 1 U of Phusion DNA Polymerase, 0.2 mM of each deoxynucleoside triphosphate, 1× PCR buffer, 5 pmol of SDM primer, 2 mM MgSO~4~ and 10% (vol/vol) dimethyl sulfoxide (DMSO). For PCR, the reaction mixture was subjected to an initial 30 sec denaturation step at 98°C, followed by 28 cycles of 10 s at 98°C, 30 s at 50°C, and 4 min at 72°C and a 10-min final elongation at 72°C. The PCR product was further treated with 5 U of *Dpn*I at 37°C for 1 hr. The *Dpn*I-treated PCR product was directly transformed into DH5α competent cells. Transformants were incubated in 5 ml LB medium containing 5 mg/L tetracycline overnight. Tetracycline resistant colonies were isolated and extracted for plasmid content. Mutant start codon in the successfully transformed plasmid was confirmed by DNA sequencing.

Pulsed-field gel electrophoresis {#s2i}
--------------------------------

All clinical *A. baumannii* isolates with the IS element in their *adeRS* operon were genotyped by the pulsed-field gel electrophoresis (PFGE). Total DNA was prepared and PFGE was performed as described previously [@pone.0049534-Seifert1]. Endonuclease *Apa*I was used to digest the bacterial DNA, and then restriction fragments were analyzed by PFGE in 1% SeaKem Gold agarose gels (Cambrex Bio Science, Rockland, ME, USA) in 0.5× TBE buffer (45 mM Tris, 45 mM boric acid, 1.0 mM EDTA, pH 8.0) using a Bio-Rad CHEF-Mapper apparatus (Bio-Rad Laboratories, Hercules, CA). Gels were stained with ethidium bromide and photographed under ultraviolet light. Dendrograms showing percentage similarity were prepared with the Molecular Analyst Fingerprinting, Fingerprinting Plus and Fingerprinting DST Software (Bio-Rad Laboratories) and were compared using the UPGMA clustering method as proposed in previous studies [@pone.0049534-Sun1], [@pone.0049534-Seifert1]. Isolates with similarity over 90% were considered to be identical; isolates with below 70% similarity (\>3 band difference) were considered to be non-clonally related, using previously described criteria [@pone.0049534-Seifert1].

Measurement of β-galactosidase activity {#s2j}
---------------------------------------

β-galactosidase activity assay was modified from the method described by Miller (1992) [@pone.0049534-Morita1]. Briefly, 0.5 mL bacterial suspension of 37°C overnight culture was placed on ice for 20 min, and then harvested by centrifugation at 8000×g for 5 min at 4°C. The pellets were re-suspended in 0.5 mL of Z buffer (60 mMNa~2~HPO~4~·7H~2~O, 40 mM NaH~2~PO~4~·H~2~O, 10 mM KCl, 1 mM MgSO~4~·7H~2~O, 50 mM β-mercaptoethanol, pH 7.0) and the OD~600~ of the resuspended cells was measured (blank against Z buffer). To lysis the cells, 0.1 mL of the cell suspension was mixed with 0.4 mL of Z buffer, 50 µL of chloroform, and 25 µL of 0.1% Sodium dodecyl sulfate, vortexed for 10 sec, and incubated at 28°C. At a time point defined as zero, 0.1 mL of ONPG (o-nitrophenyl-β-D-galactopyranoside) (Sigma-Aldrich) (4 g/L) was added to the lysed cell suspension. The reaction was stopped by adding 0.25 mL of 1 MNa~2~CO~3~ at a time defined as T and the OD was then measured at 420 nm and 550 nm using a Synergy HT multi-mode microplate reader (BioTek Instruments, Winooski, VT). The activity of β-galactosidase was calculated using the following equation: 1000×\[OD~420~−(1.75×OD~550~)\]/\[(T (min)×0.2 (mL)×OD~600~)\], expressed in Miller units.

Nucleotide sequence accession number {#s2k}
------------------------------------

The 3038 -bp DNA sequences of the *adeRS* operon of AB260 and AB293 corresponding to the IS*Aba1*-interrupted *adeS* gene were submitted to the GenBank database as accession number JQ690823 and Q690824, respectively. The 2941-bp DNA sequence of the *adeRS* operon of AB392 corresponding to the IS*Aba125*-interrupted *adeR* gene was submitted to the GenBank database as accession number JQ690825.

Results {#s3}
=======

Compatible antibiotics susceptibility with PFGE genotyping results in MRAB-C isolates {#s3a}
-------------------------------------------------------------------------------------

Antimicrobial susceptibility testing revealed that the 317 clinical MRAB-C isolates were resistant to all antibiotics tested in the Vitek-2 system. Using the FDA criteria for the agar dilution method, 130 (41%), 131 (41.3%), and 56 (17.7%) isolates were resistant, intermediate, and susceptible to TGC, respectively ([Figure 1A](#pone-0049534-g001){ref-type="fig"}). The full length of *adeRS* operon in each MRAB-C isolate was expected to be consistent in size (1.8 kb) after PCR amplification. However, the PCR products from 41 isolates were about 3.0 kb, which indicates additional DNA sequences within the *adeRS* operon. Among the 41 isolates, 38 (92.7%) isolates were resistant and 3 (7.3%) were susceptible to TGC. In a previous study, we demonstrated the expression of AdeABC efflux pump is significantly correlated with MIC of TGC in clinical isolates during the period [@pone.0049534-Sun1]. To verify the effect of AdeABC efflux pump on TGC resistance, all MRAB-C isolates were tested for their MIC of TGC in the presence of NMP, an efflux pump inhibitor ([Figure 1B](#pone-0049534-g001){ref-type="fig"}). On plates with NMP, their E-test MIC (0.5--4 mg/L) of TGC showed 2--8 folds lower values than those without NMP (8--16 mg/L). TGC resistance was therefore related to AdeABC efflux pump overexpression in these isolates. After comparing the genotype patterns by pulsed field gel electrophoresis (PFGE) with *Apa*I-digestion, the 41 isolates were classified into 3 clusters and 3 sporadic clones based on PFGE criteria ([Figure 2](#pone-0049534-g002){ref-type="fig"}). The genotypic grouping result was compatible with phenotypes of TGC susceptibility. Two major clusters (AB354-AB338 and AB92-AB335 in [Figure 2](#pone-0049534-g002){ref-type="fig"}) and one minor cluster (AB341 and AB351) contained 38 (92.7%, 38/41) of all the MRAB-C isolates that were all TGC resistant. The remaining 3 sporadic clones (AB90, AB260 and AB392) were TGC susceptible.

![Tigecycline MIC profile of the clinical *A. baumannii* isolates.\
(A) Distribution of tigecycline MIC of the clinical *A. baumannii* isolates with (black bar) and without (grey bar) insertion of additional DNA in their *adeRS* operon (B) MIC to tigecycline alone (grey bar) and to tigecycline/NMP combination (black bar) for the 41 clinical *A. baumannii* isolates with insertion of additional DNA in their *adeRS* operon.](pone.0049534.g001){#pone-0049534-g001}

![Pulsed-field gel electrophoresis (PFGE) for *Apa*I of 41 *A. baumannii* isolates with insertion of additional DNA in their *adeRS* operon.\
Dendrogram was generated by UPGMA clustering.](pone.0049534.g002){#pone-0049534-g002}

IS elements within the *adeRS* operon found by sequencing analysis {#s3b}
------------------------------------------------------------------

To determine the additional DNA insertion in *adeRS* operon, direct sequencing of *adeRS* operon PCR products showed the presence of the IS*Aba125* element within the *adeR* gene in AB392 isolates and the IS*Aba*1 element within the *adeS* gene in the remaining 40 strains ([Figure 3A](#pone-0049534-g003){ref-type="fig"}). The IS*Aba125* element was 1,087-bp in length. It contained a 969-bp open reading frame (ORF) encoding a putative transposase, and was bounded by 15-bp inverted repeat sequences which are common to members of the IS*30* group. Two 9-bp individual sequences (GGCGAATTC and TACTCTGCC) flanked the IS*Aba125* at the predicted insertion site in *adeR* gene of AB392. The presence of IS*Aba125* mediated disruptive events on the *adeR* gene in AB392, resulting in the loss function of *adeR*, and maybe affecting the expression of the AdeABC efflux pump system. The IS*Aba1* element was 1180-bp in length, containing two consecutive and overlapping ORFs, 567-bp ORF1 and 535-bp ORF2. It was therefore likely that a frame-shift is necessary to generate a unique protein as functional transposase. The IS*Aba1* was bounded by 15-bp inverted repeat sequences which are common to members of the IS*4* family ([Figure 3A](#pone-0049534-g003){ref-type="fig"}). A 9-bp duplication (ATAATTTTA) flanked IS*Aba1* at the predicted insertion site in *adeS* gene of the other isolates. The presence of IS*Aba1* mediated disruptive events on the *adeS* gene, resulting in the loss function of *adeS* gene, and maybe affecting the expression of the AdeABC efflux pump system. However, we noted the most striking difference in the distribution of TGC MIC in the isolates. Only 2 strains (AB090 and AB260) were TGC susceptible and the remaining 38 isolates were TGC resistant. Hence, it was necessary to investigate whether the phenomenon was caused by DNA mutation in the promoter region or in *adeRS* operon. Nucleotide sequences of the promoter region and the *adeRS* operon with IS*Aba1* insertion were analyzed by multiple sequence alignment. DNA sequences of the promoter region and the destroyed *adeS* gene were identical among the 38 TGC resistant isolates. However, two point mutations (Met197Ile) and (Ser200Cys) in *adeR* gene were identified in all isolates, except for the two TGC sensitive isolates.

![Alteration of the *adeRS* operons by insertion of IS*Aba125* or IS*Aba1* in multidrug resistant *A. baumannii* isolates.\
(A) Genetic scheme of wide type *adeRS* operon in ATCC 15151 and two insertion mutations. IS*Aba*125 disrupts the *adeR* gene and IS*Aba1* disrupts the adeS gene in clinical multidrug resistant *A. baumannii* isolates. Open arrows indicate coding sequences and direction of transcription. *P*ade is the promoter of the *adeABC* operon. Closed arrowheads indicate the position and orientation of the primers used in quantitative *adeR* and *adeS* real-time PCR (all positions are according to accession no. JQ690823-5 in GenBank). IRR, inverted repeat-right; IRL, inverted repeats-left; DR, direct repeat. (B) Presumed promoters in IS*Aba1* and downstream coding sequence of the truncated AdeS. The deduced amino-acid sequence is designated in a single letter code below the nucleotide sequence and the star sign indicates stop codon. The inverted repeat sequences (IRL) of IS*Aba1* are dash-underlined. The −35 and −10 motifs of promoters are indicated as numbers. *P*in is the promoter for transposase gene in IS*Aba1*, and *P*out is the promoter for the truncated AdeS derived from IS*Aba1* insertion. The truncated AdeS start codon is boxed.](pone.0049534.g003){#pone-0049534-g003}

Transcript analysis of *adeABC* operon and *adeRS* operon {#s3c}
---------------------------------------------------------

As the synergistic effect of NMP on TGC susceptibility described above, the TGC resistance may be associated with up-regulation of the AdeABC efflux pump in those isolates with their *adeS* gene destroyed by IS*Aba1*. We investigated the transcription activity of *adeRS* operon and *adeABC* operon in representative isolates with various TGC MICs using quantitative real-time RT-PCR ([Table 3](#pone-0049534-t003){ref-type="table"}). The two isolates (AB039 and AB096) were discussed in our previous research [@pone.0049534-Sun1], [@pone.0049534-Peleg2], [@pone.0049534-Hornsey1]. They both have higher MIC of TGC than strain ATCC 15151. The MICs of TGC were 2 mg/L and 16 mg/L for AB39 and AB96, respectively. Although the detail mechanism was not explored, we have demonstrated the higher MIC is proportionally correlated with the *adeB* expression level. We used these two strains simply to show the consistency of our experiment. We were still not able to identify the exact cause for their difference. In this manuscript, nonetheless, we focused on the group of isolates with an insertion element.

10.1371/journal.pone.0049534.t003

###### Relationship between tigecycline MICs and expression of *adeRS* and *adeABC* operons in clinical strains of *A. baumannii*.

![](pone.0049534.t003){#pone-0049534-t003-3}

                                                   Differential quantification of gene expression (fold)                              
  ------------------- -------------------- ------ ------------------------------------------------------- ----------- --------------- ---------------
  Without insertion        ATCC 15151       ≦0.5                           1.00                              1.00          1.00            1.00
                              AB39           2                           1.50±0.73                         0.65±0.2     24.15±5.95      42.64±22.49
                              AB96           16                          1.55±0.15                         0.67±0.05   285.75±106.12   622.03±189.32
  With insertion       AB392 (IS*Aba125*)   ≦0.5                         1.21±0.25                         0.08±0.02     0.55±0.33       1.05±0.64
                        AB260 (IS*Aba1*)     1                           1.87±0.14                         2.82±0.88     1.02±0.54       1.71±0.59
                        AB293 (IS*Aba1*)     16                          2.45±0.98                         2.12±0.35    51.32±9.21      81.75±68.78

To quantify the *adeRS* operon expression in strains with various IS element insertion, the first set of PCR primers for *adeR* gene was targeting the region between its promoter and the IS*Aba125* insertion site in AB392 ([Figure 3A](#pone-0049534-g003){ref-type="fig"}). The second set of PCR primers was targeting the terminal region of *adeS* gene after the IS*Aba1* insertion site in AB293 ([Figure 3A](#pone-0049534-g003){ref-type="fig"}). We first compared the *adeB* gene expression in TGC resistant isolates (AB096 and AB293) with the proposed basal expression in control strain ATCC 15151. The expression of *adeB* gene increased 622 times and 82 times in AB096 and AB293, respectively. In contrast, only a 42-fold, 1.1-fold and 1.7-fold increase in the *adeB* gene expression was observed in TGC susceptible clinical strains, AB039, AB392 and AB260, respectively. The *adeA* gene showed the same increasing expression pattern in TGC resistant clinical isolates as the *adeB* gene. All the TGC susceptible isolates (ATCC15151, AB260 and AB392) had less transcription of *adeA* and *adeB* consistently. In contrast, the transcription levels of the *adeA* and *adeB* genes in TGC resistant isolates were significantly higher than those in TGC susceptibility isolates (Mann-Whitney Test, *P* value \<0.05). We tried to correlate the overexpression of *adeA* and *adeB* genes with their regulatory compartment by quantifying the transcripts of *adeR* and *adeS* genes in the TGC resistant isolates. The level of transcription of *adeR* in AB260 (1.87±0.14) and AB293 (2.45±0.98) was not significantly different (Mann-Whitney Test; *P* value = 0.38). However, the *adeS* gene transcription in AB392 was 12.5-fold lower than in the ATCC 15151 control strain. Lower *adeS* transcription might result from the polar effect after an IS*Aba125* insertion in AB392. The IS*Aba1* insertion also resulted in the same polar effect after an IS*Aba1* insertion in AB260, but did not cause the same polar effect to reduce the *adeS* gene transcription in AB293. Our findings suggested that an extra promoter within the IS*aba1* element of AB293 constitutively drives the transcription for the remaining *adeS* gene fragment.

A truncated AdeS predicted by DNA sequencing {#s3d}
--------------------------------------------

To determine the structure and function domain of AdeS, we analyzed the full adeS gene sequence in ATCC 15151 by the NCBI tool and the transmembrane domain prediction tool. The N-terminus of the AdeS contained two transmembrane segments (amino acid positions 9--36 and 58--85), which suggests that AdeS is a membrane anchored protein. The C-terminus of AdeS after the second transmembrane segment was the transmitter compartment containing a phosphorylatable HisKA domain and an ATP -binding domain. The insertion site of IS*Aba*1 was located between the second transmembrane segment and the transmitter compartment in AB293. Also, a *P*out promoter overlapping with *Pin* promoter was found near left inverted repeat sequence (IRL) within the IS*Aba1* element ([Figure 3B](#pone-0049534-g003){ref-type="fig"}). By analyzing the downstream sequences of the *P*out promoter, we predicted an ORF encoding a protein with 229 amino acids by ORF finder. The amino acid sequence of the predicted protein was the same as the carboxyl-terminal transmitter domain of AdeS protein. We deduced a truncated AdeS driven by the *P*out promoter in the IS*Aba1* element ([Figure 3B](#pone-0049534-g003){ref-type="fig"}). The predicted protein contained neither transmembrane helices nor a signal peptide. It was suggested to be a truncated protein within the cytoplasm. The truncated AdeS shared 100% amino acid identity with the kinase sensor protein annotated as a hypothetical protein of the MRAB-C strain 1656-2 (GenBank accession number ADX03920). We further analyzed the biological function of the truncated AdeS protein by investigating its possible relationship with two point mutations of AdeR in determining TGC resistance.

Acquired TGC resistance induced by coexistence of the truncated AdeS and mutated AdeR {#s3e}
-------------------------------------------------------------------------------------

To further assess the relationship between the truncated AdeS and mutated AdeR in TGC resistant isolates, DNA fragments of the full length *adeRS* operon and the *adeR* gene from different strains (wt, AB260 and AB293) were cloned into the pRS system to construct pRS-*adeRS* (wt, AB260, AB293) and pRS-*adeR* (wt, AB260, AB293), respectively ([Figure 4A](#pone-0049534-g004){ref-type="fig"}). The predicted truncated *adeS* operon of AB293 was also cloned into pRS to generate pRS-Pout-truncated *adeS*. The pRS-*adeRS* (AB293) was digested with *Sph*I and was self-ligated to generate pRS-*P*ade-*P*out-truncated *adeS*. The *adeRS* opreon of ATCC 15151 was destroyed to generate a mutant bacterial strain (ABmut02) by homologous recombination with a suicide plasmid. These recombinants and the ABmut02 mutant strain were used to assess the regulation of AdeABC efflux pump expression. The recombinant plasmids were transformed respectively into ATCC 15151 and ABmut02 to obtain the transformed strains. The transformed strains were then tested for their antimicrobial susceptibilities. Results of the antibiotic susceptibility assays were summarized in [Table 4](#pone-0049534-t004){ref-type="table"}. Assays on ATCC15151 wild type strain showed an 8-fold TGC MIC increase after transforming ATCC 15151 with pRS-*adeRS* (AB260), pRS-*adeRS* (AB293), pRS-Pade-Pout-truncated *adeS* or pRS-Pout-truncated adeS. The AdeRS-destroyed mutant ABmut02 shared the same TGC MIC with wild type ATCC 15151 after transforming with the pRS-*adeRS* (AB260) or pRS-*adeRS* (AB293). However, contrary to expectation, transformation with pRS-*P*ade-*P*out-truncated\_*adeS* or pRS-*P*out-truncated\_*adeS* did not show higher TGC MIC in ABmut02. We demonstrated that the truncated AdeS must cooperate with AdeR to induce TGC resistance. And the two point mutations in AdeR were proven to have no significant effect on its interaction with the truncated AdeS. To determine whether the multidrug resistance was directly induced by the truncated AdeS in the pRS system, we disrupted the start codon of the truncated AdeS by site directed mutagenesis. We found 16-fold lower TGC MIC and multidrug MIC reduction in ATCC 15151 transformed with the start codon disrupted mutant, pRS-Pout-truncated_adeS (SDM). Accordingly, we suggest that truncated AdeS is associated with acquired TGC and multidrug resistance.

![Construction of the pRS recombinant series.\
(A) Strategies for obtaining a series of DNA fragments containing promoter region of *adeABC* operon and a series of *adeRS* operon variants from wild type (wt) ATCC 15151 and drug resistant strains (260, 293) by PCR. Open arrows denote coding sequences and indicate the direction of transcription in the bacterial genome. The white rectangle box denotes the region of *P*ade promoter (*P*ade and *P*re). The red rectangle box denotes the promoter region in IS*Aba1* (*P*in and *P*out). Arrows following the rectangle boxes together indicate the PCR fragments used to generate pRS recombinant series. (B) Construction map of the promoter-less *lacZ* gene of pRS system. The pRS system was derived from pS01, which remove *lacI^q^*-P~T7~ promoter by engineered *Sma*I and *Bam*HI cutting. The pRS system was obtained and used for cloning PCR fragments into upstream of the promoter-less *lacZ* gene of pRS system between *Sma*I and *Bam*HI restriction sites. The rectangle box indicates the region of promoters. The region of *P*ade promoter region contains two overlapped promoters in opposite direction (*P*ade and *P*re). Two overlapped promoters, *P*in and *P*out, were in the region of promoter region in IS*Aba1*. The expression level of *lacZ* gene represented for the activity of promoter of *adeABC* operon or *P*in promoter of IS*Aba1*.](pone.0049534.g004){#pone-0049534-g004}

10.1371/journal.pone.0049534.t004

###### Antimicrobial susceptibilities of the various *A. baumannii* transformants.

![](pone.0049534.t004){#pone-0049534-t004-4}

                                                                     MIC (mg/liter) of                        
  ---------------------------- ------------------------------------ ------------------- -------- ---- ------- -------
  ATCC 15151 (wt *adeRS*)                   no plasmid                     0.25           0.25    2    ≦0.25   ≦0.12
                                               pS01                        0.125         0.0625   2    ≦0.25   ≦0.12
                                         pRS-*adeRS* (wt)                  0.25          0.125    2    ≦0.25   ≦0.12
                                       pRS-*adeRS* (AB260)                   2            0.25    16     1     0.25
                                       pRS-*adeRS* (AB293)                   2            0.25    16     1     0.25
                                         pRS-*adeR* (wt)                   0.25          0.125    2    ≦0.25   ≦0.12
                                        pRS-*adeR* (AB260)                 0.25          0.125    2    ≦0.25   ≦0.12
                                        pRS-*adeR* (AB293)                 0.25          0.125    2    ≦0.25   ≦0.12
                                pRS-P*ade*-P*out*-truncated *adeS*           2            0.25    16    0.5    0.25
                                   pRS-P*out*-truncated *adeS*               2            0.25    16    0.5    0.25
                                pRS-P*out*-truncated *adeS* (SDM)          0.25          0.125    2    ≦0.25   ≦0.12
  ABmut02 (*adeRS* destruct)                no plasmid                     0.25           0.25    2    ≦0.25   ≦0.12
                                               pS01                        0.25           0.25    2    ≦0.25   ≦0.12
                                         pRS-*adeRS* (wt)                  0.125         0.0625   2    ≦0.25   ≦0.12
                                       pRS-*adeRS* (AB260)                   2            0.25    16    0.5    0.25
                                       pRS-*adeRS* (AB293)                   2            0.25    32     1     0.25
                                         pRS-*adeR* (wt)                   0.125         0.0625   2    ≦0.25   ≦0.12
                                        pRS-*adeR* (AB260)                 0.125         0.0625   2    ≦0.25   ≦0.12
                                        pRS-*adeR* (AB293)                 0.125         0.0625   2    ≦0.25   ≦0.12
                                  pRS-P*ade*-Pout-truncated adeS           0.125         0.0625   2    ≦0.25   ≦0.12
                                   pRS-P*out*-truncated *adeS*             0.125         0.0625   2    ≦0.25   ≦0.12
                                pRS-P*out*-truncated *adeS* (SDM)          0.125         0.0625   2    ≦0.25   ≦0.12

Quantifying the *P*ade promoter activity by the β-galactosidase assay {#s3f}
---------------------------------------------------------------------

To further differentiate the promoter effect from either *P*ade of *adeABC* operon or *P*in of ISaba1, we quantified *adeA* and *adeB* gene expression in all the transformants listed in [Table 4](#pone-0049534-t004){ref-type="table"}. We constructed a *lacZ* gene reporter system instead of laborious quantification RT-PCR of *adeA* and *adeB*. The *lacZ* gene was cloned as a substitute for the *adeABC* gene in the pRS series ([Figure 4B](#pone-0049534-g004){ref-type="fig"}). Then we were able to assay the promoter effect by directly quantifying β-galactosidase activity. The β-galactosidase activities in ATCC 15151 strain with pS01 (13±7 units) and in ABmut02 strain with pS01 (12±6 units) were measured as background. In ATCC 15151, β-galactosidase activities increased about 172-fold (2068±290 units), 149-fold (1783±508 units) and 123-fold after transformation with pRS-*adeRS* (260), pRS-*adeRS* (293), and pRS-Pade-Pout-truncated *adeS*, respectively (Mann-Whitney Test; *P* value \<0.05). In ABmut02, β-galactosidase activities also increased about 128-fold (1669±766 units) and 135-fold (1757±546 units) after transformation with pRS-*adeRS* (260) and pRS-*adeRS* (293), respectively (Mann-Whitney Test; *P* value \<0.05) ([Figure 5](#pone-0049534-g005){ref-type="fig"}). Transformation of pRS-*P*ade-*P*out-truncated *adeS* can only increase β-galactosidase activitiy by 20 fold while AdeR is lacking in ABmut02 strain (Mann-Whitney Test; *P* value \<0.05). The β-galactosidase activity did not increase while being transformed with the recombinant plasmids expressing adeR only (wt, 260, 293) into either ATCC 15151 or ABmut02 strains. These results suggested that the expression of the *adeABC* efflux pump was directly controlled by the two-component system, truncated AdeS and AdeR. The expression of β-galactosidase activity was significantly higher in ATCC15151 with pRS-*Pade*-*P*out-truncated *adeS* than with pRS-*P*out-truncated *adeS* (Mann-Whitney Test; *P* value \<0.05). And the lower expression of β-galactosidase activity was observed in ABmut02 with pRS-*P*ade-*P*out-truncated *adeS* than with pRS-*P*out-truncated *adeS* (Mann-Whitney Test; *P* value \<0.05). These results suggested that AdeR protein is necessary for stimulating *Pade* promoter and enhancing the expression of the *adeABC* efflux pump. In order to rule out the possibility of *P*in promoter of IS*Aba1* on enhancing the expression of *adeABC* operon, we only increased the β-galactosidase activity of ATCC 15151 and ABmut02 transformed with the *P*in containing plasmid pRS-*P*out-truncated\_*adeS* by 31-fold (374±46 units) and 36-fold (465±48 units), respectively. The β-galactosidase assay successfully quantified the significantly higher *lacZ* activity in the strain transformed with pRS-*adeRS* compared with pRS-*P*out-truncated *adeS*. The biological function of truncated adeS was further demonstrated besides converting the MIC presentation, and the truncated adeS with coexistence of adeR can constitutively stimulate the promoter *P*ade to express the *lacZ* gene.

![β-galactosidase activities of transformed strains with various pRS recombinants.\
ATCC 15151 and ABmut02 cells transformed with various pRS recombinants were grown in LB medium at 37°C overnight. The measurement of β-galactosidase activity was repeated at least three times, and the mean values of one representative experiment performed in triplicate are reported (error bars indicate the standard deviation). The measurement of β-galactosidase activity represents for the activity driven by either *P*ade of *adeABC* operon or *P*in of IS*Aba1*.](pone.0049534.g005){#pone-0049534-g005}

Discussion {#s4}
==========

Antibiotic resistance is a major challenge in treating infections caused by *A. baumannii* [@pone.0049534-Peleg1]. The *adeABC* operon is located in chromosomal DNA and it endorses the intrinsic low-level expression in *A. baumannii*. [@pone.0049534-Coyne1], [@pone.0049534-Wieczorek1]. The expression of AdeABC efflux pump is tightly regulated by the two-component regulatory system AdeR-AdeS, encoded by the *adeRS* operon that is located upstream of *adeABC* operon and transcribed in the opposite direction [@pone.0049534-Coyne1], [@pone.0049534-Wieczorek1], [@pone.0049534-Marchand1].. The overexpression of the AdeABC efflux pump, responsible for reducing accumulation of many antibiotics, is an efficient mechanism for multidrug resistance in *A. baumannii* [@pone.0049534-Magnet1]. AdeS is a membrane-integrated sensor protein with a histidine kinase domain which converts and transfers environmental stimuli to a response regulator AdeR for regulating the AdeABC gene expression [@pone.0049534-Coyne1], [@pone.0049534-Wieczorek1]. On the basis of our current data, we proposed an N-terminal truncated AdeS generated by the Pout promoter within the IS*Aba1* insertion of *adeS* gene. The truncated AdeS protein was able to activate AdeR and then enhance the *adeABC* gene expression.

Ruzin et al. [@pone.0049534-Ruzin1] reported they found the disruption of AdeS by the insertion sequence IS*Aba1* in two TGC-resistant isolates of *Acinetobacter calcoaceticus*--*A. baumannii* complex. The AdeABC pumps were overexpressed in these strains and associated with TGC resistant. However, the prevalence, genotype and mechanism of the strain with an IS*Aba1* insertion in *adeS* gene had not been well investigated. In this study, we found 41 of the 317 isolates contained DNA insertions in their *adeRS* operon. Besides the IS*Aba1* insertion of adeS gene in 40 isolates as presumed, the remaining one isolate was found with IS*Aba125* insertion in its *adeR* gene. Compared with the TGC susceptibility phenotype, we found that 38 of the above 40 isolates accounted for 29.2% (38/130) of the TGC resistant isolates, and they demonstrated differences in the PFGE patterns. This result may indicate a common ancestor shared by these isolates with IS*Aba1* insertion in *adeS* gene.

Previous studies including ours have indicated that the sequence of AdeR and AdeS are widely variable in clinical isolates, but several mutations are still recommended for causing overexpression of the AdeABC efflux pump [@pone.0049534-Sun1], [@pone.0049534-Peleg2], [@pone.0049534-Hornsey1]. Most of the publications describe point mutations in the sensor domain (Asp30Gly), in the linker domain (Aln94Val) between the recognition domain and the histidine box, and in the histidine box (Tro153Met) of the AdeS [@pone.0049534-Marchand1], [@pone.0049534-Coyne3]. A mutation (Pro116Leu) in AdeR is also reported to cause *adeABC* operon overexpression likely due to altering the structural conformation of the regulator [@pone.0049534-Marchand1]. In addition, AdeR mutation (Aln91Val) and AdeS mutation (Gly103Asp) occur concurrently in a susceptibility conversion strain after exposure to TGC. However, the detail interaction among these mutations has not been ascertained [@pone.0049534-Hornsey1]. Although we found two new mutations (Met197Ile) and (Ser200Cys) on the DNA binding domain of AdeR protein of all TGC resistant strains included in this study, strain AB260 with the same mutations showed lower expression level of the *adeABC* operon and was susceptible to TGC. However, the transformed strains with pRS-adeRS(AB293) and with pRS-adeRS(AB260) were presented with the presumed higher MIC to TGC. We therefore suggested that the *adeABC* operon expression in the susceptible strain AB260 might be inhibited by some unknown mechanism. Future studies will focus on analyzing the inhibition mechanism of *adeABC* operon expression in the TGC susceptibility strain.

IS*Aba1* copies were found in the chromosome and plasmids, which have been known to be related to antibiotic resistance only in *Acinetobacter* spp [@pone.0049534-Segal2]. Previous genome-wide studies on evaluating the drug resistance mechanism in clinical *A. baumannii* isolates found multidrug resistant isolates carry more IS*Aba1* elements copies (9 to 428) than clinical susceptible strains and laboratory strains [@pone.0049534-Adams1], [@pone.0049534-Park1], [@pone.0049534-Adams2], [@pone.0049534-Vallenet1]. The IS*Aba1* element flanks an antibiotic resistant gene and is involved in the overexpression of the genes from an outward-facing promoter, *P*out in the IS element. Another example, disruption of an antibiotics influx pump protein, designated CarO, has also been reported by the IS*Aba1* element insertional inactivation [@pone.0049534-Mussi1]. Other IS*Aba1* insertions are polymorphic and are thus unlikely to be directly related to drug resistance in these strains [@pone.0049534-Murat1]. Some IS*Aba1* insertion locations are also found in or adjacent to hypothetical protein genes. Previous genome-wide studies have identified an IS*Aba1* insertion in the *adeS* gene and even a presumed sensor kinase protein [@pone.0049534-Adams1], [@pone.0049534-Park1]. In this study, a similar IS*Aba1* insertion into *adeS* was demonstrated to generate a truncated AdeS which shared the same amino acid sequence as the predicted sensor kinase protein of the genome-wide study [@pone.0049534-Park1]. We therefore suggested that the *A. baumannii* strain with a truncated *adeS* gene through IS*Aba1* insertion may have a worldwide distribution and require further investigation.

Instead of laboriously comparing the possible genomic difference among *A. baumannii* strains, we converted the reference strain ATCC 15151 to an AdeRS-knockout laboratory strain, ABmut02. A series of pRS recombinants carrying different *adeRS* fragments and the *lacZ* reporter gene were then able to be analyzed for their regulatory effect in the mutant strain. By directly quantifying the expression of the *lacZ* gene, we can compare the triggering effect of various *adeRS* operons on the *adeABC* promoter. Because *adeR* and *adeS* operon array sequentially after the same promoter, we did not obtain a laboratory strain solely with *adeR* gene disruption. The MIC of TGC can be as high as 16 mg/L for clinical resistant isolates. However, MICs of TGC were only mildly elevated (MIC = 2 mg/L, 8-folds) after transforming the truncated AdeS into ATCC 15151 and its adeRS-knockout derivative. The partially resistance-converting result suggests there are other mechanisms affecting the AdeABC efflux system. We presume some inhibitors offset the truncated AdeS effect in ATCC 15151 and AB260, but not in AB293. This inhibitor proposal may explain why isolate AB260 only demonstrates moderate MIC to TGC (1 mg/L) instead of MIC 16 mg/L in AB293. In addition, boosting AdeS by transforming a plasmid encoded the truncated *adeS* operon into ATCC 15151 did convert its susceptibility to TGC, while the same plasmid alone was unable to overcome the proposed inhibitor in ATCC 15151 mutant (ABmut02) with the destructed *adeRS*. The observed alteration of MIC to TGC for those artificial transformants supports our proposal indirectly. However, we need more direct evidence to prove this proposal. Moreover, an extraordinary efflux pump or other resistance mechanism may coexist to result in the aberrantly high MIC to TGC in AB293.

In this report, we have shown the distribution of multidrug resistant *A. baumannii* with the IS*Aba1* insertion in *adeS* gene in Taiwan. We have also demonstrated the existence of a truncated AdeS and its biological function. The truncated AdeS is able to induce multidrug resistance by constitutively stimulating the expression of AdeABC efflux pump through motivating the AdeR to interact with and activate the *adeABC* promoter. Our findings not only confirm the previously presumed additional *adeS* gene after IS*Aba1* insertion, but also further characterize it as another mechanism for IS*Aba1*-related antibiotic resistance. As the two-component system is a vital structure of the bacteria and is used to adapt to changing environmental conditions, insight and applications resulting from studies on *A. baumannii* will probably be broadly applicable to other bacteria.
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